# Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

> **NCT02171663** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 43 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT02171663
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2015-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171663, "Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02171663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*